Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

European Research Council grant · Running

D-MAP Dissecting the Functional Role of Mucosal IgA Clonal and Glycoprofiles for Effective Humoral Mucosal Protection

Coordinator
Karolinska Institutet, Sweden
Runs
1 January 2025 to 31 December 2029
Status
Running
EU funding
€1.5m
Total cost
€1.5m
Partners
4 organisations in 2 countries
Type
European Research Council grant
Grant agreement
101164772

What the project is doing

In the project's own words, from its summary on CORDIS.

Numerous mucosal vaccines and IgA-based monoclonal antibodies aimed at a robust immunity within the respiratory tract are in development to combat viral endemics and pandemics. However, investigations into humoral immunity have predominantly focused on circulating antibodies, particularly those of the IgG isotype. This has left a significant void in our understanding of the role of mucosal IgA proteoforms in conveying effective immune protection.

This crucial knowledge gap deprives vaccine and antibody development of crucial determinants or immune characteristics to replicate. In response to this, we will conduct in-depth investigations of mucosal IgA including in vitro and in vivo functional evaluations. We will capitalize on recent advances in liquid chromatography and mass spectrometry-based approaches for the detailed characterization of mucosal IgA clonal repertoires and glycosylation profiles, a field that has remained completely unexplored until now, B-cell receptor sequencing, monoclonal IgA glycoengineering and in vitro functional assays.

We will take advantage of our unparalleled biobank of human nasal secretion samples with clear documentations of infection outcomes on an individual level. What sets our approach apart is thereby the unprecedented molecular-level characterization of IgA, directly linked to their in vitro functionality and pre-defined clinical outcomes, which clearly surpasses current state-of-the-art. By harnessing our in-depth characterization of mucosal IgA coupled to functional traits, we will generate IgA templates with enhanced binding and neutralization capabilities as well as functionally advantageous Fc effector potencies.

Our overarching aim is to provide molecular-level blueprints for protective monoclonal IgA-antibodies, enabling the fine-tuning of vaccine formulations and monoclonal antibody generation with a higher degree of accuracy, ultimately enhancing their efficacy and safety.

Topics

Who is involved

OrganisationCityCountryRole
Karolinska InstitutetStockholmSwedenCoordinator
Academisch Ziekenhuis LeidenLeidenNetherlandsParticipant
Stichting Sanquin BloedvoorzieningAmsterdamNetherlandsParticipant
Danderyds Sjukus AktiebolagStockholmSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI